Nur SOYER, Püsem PATIR, Ayşe UYSAL, Mustafa DURAN, Hatice Demet Kiper ÜNAL, İsabel Raika Durusoy ONMUŞ, Murat TOMBULOĞLU, Fahri ŞAHİN, Mahmut TÖBÜ, Filiz VURAL, Güray SAYDAM

Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience

Öz Background/aim: In Turkey, lenalidomide plus dexamethasone (RD) has been used to treat relapsed/refractory multiple myeloma (RRMM) since 2010. This retrospective, single-center study evaluated the efficacy and tolerability of RD in patients with RRMM between October 2010 and June 2016. Materials and methods: Patients' records were reviewed, and overall (OS) and progression-free survival (PFS) were assessed. Results: One hundred and twenty patients (71 males; 59.2%) were included in the study. The median number of prior lines of treatment was one (1-4); 72 patients (60.0%) received RD as second-line therapy and 51 patients (42.5%) had previously undergone autologous stem cell transplantation (ASCT). The overall response rate was 72.5%, with 19% of these patients achieving a complete response. The median length of follow-up and duration of response to RD was 14 months and 19 months, respectively. Median OS and PFS were 32 and 21 months, respectively. Prior ASCT, an overall response, and treatment with RD for >12 cycles were identified as independent prognostic factors for OS and PFS. Adverse events (AEs) occurred in 69 (57.5%) and 14 patients (11.7%) discontinued treatment due to AEs. Conclusions: We found RD to be safe, well tolerated, and effective in RRMM in everyday clinical practice in Turkey.

Anahtar Kelimeler:

Lenalidomide, dexamethasone, multiple myeloma, efficacy, safety

Tam Metin

Kaynak Göster

Bibtex	@ { tbtkmedical576723, journal = {Turkish Journal of Medical Sciences}, issn = {1300-0144}, eissn = {1303-6165}, address = {}, publisher = {TÜBİTAK}, year = {2018}, volume = {48}, pages = {777 - 785}, doi = {}, title = {Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience}, key = {cite}, author = {Soyer, Nur and Patır, Püsem and Uysal, Ayşe and Duran, Mustafa and Ünal, Hatice Demet Kiper and Onmuş, İsabel Raika Durusoy and Tombuloğlu, Murat and Şahin, Fahri and Töbü, Mahmut and Vural, Filiz and Saydam, Güray} }
APA	Soyer, N , Patır, P , Uysal, A , Duran, M , Ünal, H , Onmuş, İ , Tombuloğlu, M , Şahin, F , Töbü, M , Vural, F , Saydam, G . (2018). Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience . Turkish Journal of Medical Sciences , 48 (4) , 777-785 . Retrieved from https://dergipark.org.tr/tr/pub/tbtkmedical/issue/45702/576723
MLA	Soyer, N , Patır, P , Uysal, A , Duran, M , Ünal, H , Onmuş, İ , Tombuloğlu, M , Şahin, F , Töbü, M , Vural, F , Saydam, G . "Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience" . Turkish Journal of Medical Sciences 48 (2018 ): 777-785 <https://dergipark.org.tr/tr/pub/tbtkmedical/issue/45702/576723>
Chicago	Soyer, N , Patır, P , Uysal, A , Duran, M , Ünal, H , Onmuş, İ , Tombuloğlu, M , Şahin, F , Töbü, M , Vural, F , Saydam, G . "Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience". Turkish Journal of Medical Sciences 48 (2018 ): 777-785
RIS	TY - JOUR T1 - Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience AU - Nur Soyer , Püsem Patır , Ayşe Uysal , Mustafa Duran , Hatice Demet Kiper Ünal , İsabel Raika Durusoy Onmuş , Murat Tombuloğlu , Fahri Şahin , Mahmut Töbü , Filiz Vural , Güray Saydam Y1 - 2018 PY - 2018 N1 - DO - T2 - Turkish Journal of Medical Sciences JF - Journal JO - JOR SP - 777 EP - 785 VL - 48 IS - 4 SN - 1300-0144-1303-6165 M3 - UR - Y2 - 2021 ER -
EndNote	%0 Turkish Journal of Medical Sciences Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience %A Nur Soyer , Püsem Patır , Ayşe Uysal , Mustafa Duran , Hatice Demet Kiper Ünal , İsabel Raika Durusoy Onmuş , Murat Tombuloğlu , Fahri Şahin , Mahmut Töbü , Filiz Vural , Güray Saydam %T Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience %D 2018 %J Turkish Journal of Medical Sciences %P 1300-0144-1303-6165 %V 48 %N 4 %R %U
ISNAD	Soyer, Nur , Patır, Püsem , Uysal, Ayşe , Duran, Mustafa , Ünal, Hatice Demet Kiper , Onmuş, İsabel Raika Durusoy , Tombuloğlu, Murat , Şahin, Fahri , Töbü, Mahmut , Vural, Filiz , Saydam, Güray . "Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience". Turkish Journal of Medical Sciences 48 / 4 (Ağustos 2018): 777-785 .
AMA	Soyer N , Patır P , Uysal A , Duran M , Ünal H , Onmuş İ , Tombuloğlu M , Şahin F , Töbü M , Vural F , Saydam G . Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience. Turkish Journal of Medical Sciences. 2018; 48(4): 777-785.
Vancouver	Soyer N , Patır P , Uysal A , Duran M , Ünal H , Onmuş İ , Tombuloğlu M , Şahin F , Töbü M , Vural F , Saydam G . Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience. Turkish Journal of Medical Sciences. 2018; 48(4): 777-785.
IEEE	N. Soyer , P. Patır , A. Uysal , M. Duran , H. Ünal , İ. Onmuş , M. Tombuloğlu , F. Şahin , M. Töbü , F. Vural ve G. Saydam , "Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience", Turkish Journal of Medical Sciences, c. 48, sayı. 4, ss. 777-785, Ağu. 2018